Welcome to our dedicated page for Zimmer Biomet Holdings news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet Holdings stock.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) is a preeminent global leader in musculoskeletal healthcare. Headquartered in Warsaw, Indiana, Zimmer Biomet has been at the forefront of advancing bone and joint health for nearly 90 years. The company designs, manufactures, and markets a comprehensive range of orthopedic implants and surgical equipment, addressing joint reconstruction, bone repair, sports medicine, spine, and dental reconstruction. Its innovative product portfolio includes the ROSA® Robotics systems for knee, hip, and shoulder replacements, and the TMINI Miniature Robotic System for total knee arthroplasty.
Zimmer Biomet's latest endeavors include the establishment of a dedicated Health Equity division in 2023, which aims to integrate health equity into the company's core strategies and operations. This division has already made significant strides by assembling a strategic advisory board and developing the Community Centered Care (C3) framework to increase patient access to quality care in underserved communities.
In addition, Zimmer Biomet has recently partnered with top pickleball organizations in the U.S., underscoring its commitment to joint health and well-being for the growing community of pickleball players. The company also announced a strategic alliance with CBRE Group, Inc. to expand orthopedic ambulatory surgery centers across the country, and a collaboration with RevelAi Health to commercialize AI-powered engagement solutions aimed at advancing value-based orthopedic care and health equity.
Financially, Zimmer Biomet has demonstrated robust performance, with first-quarter 2024 net sales amounting to $1.889 billion, a 3.2% year-over-year increase. The company continues to focus on innovation, operational excellence, and strategic partnerships to drive growth and enhance shareholder value. For more information, visit www.zimmerbiomet.com or follow them on LinkedIn and Twitter.
Zimmer Biomet Holdings, Inc. (ZBH) reported first quarter 2022 net sales of $1.663 billion, marking a 3.9% increase year-over-year. Adjusted diluted earnings per share were $1.61, while diluted earnings per share stood at $0.35.
The company raised its full-year guidance, now projecting revenue growth of (1.5)% to 0.5% and adjusted diluted EPS of $6.65 to $6.85. The spinoff of ZimVie was completed on March 1, 2022, and notable innovations such as WalkAI™ were launched, enhancing the company's digital offerings.
Zimmer Biomet Holdings (NYSE: ZBH) will present at the BofA Securities Healthcare Conference on May 11, 2022, at 5:00 p.m. Eastern Time. The presentation will feature Chairman, President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay. A live webcast will be available on the company's Investor Relations website and will be archived for later viewing. Zimmer Biomet is a leader in medical technology, focused on enhancing mobility and health through innovative products.
ZBH has scheduled its first-quarter earnings conference call for May 3, 2022, at 8:30 a.m. ET. A news release detailing financial results will be published at 6:30 a.m. ET on the same day. Investors can access the live audio webcast via the Investor Relations website. The conference call offers a dial-in option for participants in the U.S. and Canada. The archive of the webcast will be available post-conference. Zimmer Biomet operates in over 25 countries and sells in more than 100 countries.
Zimmer Biomet Holdings (ZBH) has launched WalkAI, an innovative AI model designed to predict patients' gait speed outcomes 90 days post-hip or knee surgery. Utilizing a proprietary algorithm and data from the ZBEdge database, WalkAI offers daily personalized predictions, helping healthcare professionals identify patients who may not follow typical recovery patterns. This model enhances patient care management through the mymobility platform and represents a significant step in Zimmer Biomet's AI strategy.
Zimmer Biomet Holdings announced the successful spinoff of ZimVie, its former Dental and Spine business, effective March 1, 2022. ZimVie will commence trading on Nasdaq under the symbol 'ZIMV.' Shareholders received one ZimVie share for every ten Zimmer Biomet shares held as of February 15, 2022. Bryan Hanson, CEO, emphasized that this strategic move is expected to enhance revenue growth and create shareholder value for both Zimmer Biomet and ZimVie. The spinoff distributes 80.3% of ZimVie's shares to existing Zimmer Biomet shareholders, with proceeds from fractional shares sold in the market.
ZimVie will replace Tabula Rasa Healthcare in the S&P SmallCap 600 index on March 2, 2022. This change comes as Zimmer Biomet Holdings spins off ZimVie, effective March 1, 2022. Post spin-off, Zimmer Biomet will continue to be a part of the S&P 500 index. Tabula Rasa Healthcare is being removed due to its lack of representation in the small-cap market.
Zimmer Biomet Holdings has announced a quarterly cash dividend of $0.24 per share for the first quarter of 2022. This dividend will be payable on April 29, 2022, to stockholders who are on record as of March 29, 2022. The company continues to position itself as a leader in medical technology, providing innovative products aimed at improving health and mobility. With a legacy spanning over 90 years, Zimmer Biomet strives to enhance the patient experience through its advanced digital and robotic technologies.
ZimVie, set to be a standalone publicly traded company from Zimmer Biomet (NYSE: ZBH), held its first Investor Day on February 7, 2022. The event highlighted its Spine and Dental offerings, market opportunities, and financial strategy. For 2022, ZimVie projects revenues of $1.0 billion, maintaining levels from 2021, with an adjusted EBITDA margin of 13.1% to 13.6%. Adjusted EPS is forecasted between $2.10 and $2.30. The ongoing COVID-19 pandemic presents risks to these projections as ZimVie aims to innovate within the $20 billion global dental and spine markets.
Zimmer Biomet Holdings has announced a dividend distribution of 80.3% of ZimVie Inc. shares to its shareholders on record as of February 15, 2022. Each shareholder will receive one share of ZimVie for every ten shares of Zimmer Biomet they own. The distribution will occur on March 1, 2022, with no fractional shares given; instead, fractional shares will be sold, and proceeds distributed as cash. ZimVie will begin 'when-issued' trading on NASDAQ on February 14, 2022, under the symbol 'ZIMVV'. Regular trading of ZimVie is set for the distribution date under 'ZIMV'.
Zimmer Biomet Holdings (NYSE: ZBH) reported its financial results for Q4 and the full year ended December 31, 2021. Q4 net sales fell to $2.038 billion, a 2.3% decrease year-over-year, while FY2021 sales rose 11.6% to $7.836 billion. The company faced a net loss of $84 million in Q4, although adjusted earnings were $409.2 million. Key challenges included impacts from China's volume-based procurement and ongoing pandemic pressures. The planned spin-off of its Dental and Spine units into a new entity, ZimVie, is set for March 1, 2022.
FAQ
What is the current stock price of Zimmer Biomet Holdings (ZBH)?
What is the market cap of Zimmer Biomet Holdings (ZBH)?
What does Zimmer Biomet do?
Where is Zimmer Biomet headquartered?
What are Zimmer Biomet's latest innovations?
What is Zimmer Biomet's focus on health equity?
How did Zimmer Biomet perform financially in the first quarter of 2024?
What are Zimmer Biomet's partnerships?
What is the ROSA® Robotics system?
What is the Community Centered Care (C3) framework?
What is Zimmer Biomet's role in pickleball?
How does Zimmer Biomet contribute to innovation in healthcare?
